Table Graph
      published meta-analysis   sensitivity analysis   studies

baloxavir marboxil in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsLou Y, 2020 1.00 [0.02; 55.80] 1.00[0.02; 55.80]Lou Y, 202010%20NAnot evaluable clinical improvement (14-day)detailed resultsLou Y, 2020 1.50 [0.26; 8.82] 1.50[0.26; 8.82]Lou Y, 202010%20NAnot evaluable clinical improvement (7-day)detailed resultsLou Y, 2020 1.00 [0.05; 18.57] 1.00[0.05; 18.57]Lou Y, 202010%20NAnot evaluable mechanical ventilationdetailed resultsLou Y, 2020 2.11 [0.06; 70.98] 2.11[0.06; 70.98]Lou Y, 202010%20NAnot evaluable viral clearance by day 14detailed resultsLou Y, 2020 0.12 [0.01; 2.86] 0.12[0.01; 2.86]Lou Y, 202010%20NAnot evaluable viral clearance by day 7detailed resultsLou Y, 2020 1.50 [0.26; 8.82] 1.50[0.26; 8.82]Lou Y, 202010%20NAnot evaluable ICU admissiondetailed resultsLou Y, 2020 2.11 [0.06; 70.98] 2.11[0.06; 70.98]Lou Y, 202010%20NAnot evaluable serious adverse eventsdetailed resultsLou Y, 2020 2.25 [0.38; 13.47] 2.25[0.38; 13.47]Lou Y, 202010%20NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-04-23 17:58 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 514 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons